Exhibit 99.1 SS Innovations Reports Second Quarter 2025 Financial Results Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth ● Revenue increased 85.6% to $15.1 million from $8.1 million in the first half of 2024. ● Gross margin expanded to 46.3% from 26.6% in the first half of 2024. ● Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024. ● Net loss of $5.9 milli ...

Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth FORT LAUDERDALE, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-42615 SS INNOVATIONS INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) | Florida | 47-3478854 | | --- | --- | | (State or Other Jurisdiction of | (I ...

Core Insights - SS Innovations International, Inc. has successfully completed the world's first intercontinental robotic cardiac telesurgery, showcasing the capabilities of its SSi Mantra 3 surgical robotic system [1][4][6] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [1][8] - The company has received regulatory approval from India's Central Drugs Standard Control Organization for both teleproctoring and telesurgery, distinguishing it from other surgical robotic companies [7] Surgical Achievements - The recent cardiac procedure involved a robotic atrial septal defect closure performed remotely from Strasbourg, France to Indore, India, covering a distance of over 4,000 miles [2][3] - To date, SS Innovations has completed 35 telesurgeries, including 10 cardiac procedures, demonstrating the effectiveness of the SSi Mantra system in complex surgeries [6] Technological Features - The SSi Mantra surgical robotic system includes advanced features such as modular robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models, enhancing surgical precision and safety [12]

Core Viewpoint - SS Innovations International, Inc. successfully completed the world's first intercontinental robotic cardiac telesurgery, demonstrating the advanced capabilities of its SSi Mantra 3 surgical robotic system and paving the way for improved access to complex cardiac care globally [1][4]. Company Achievements - The cardiac procedure performed was a robotic atrial septal defect closure, conducted remotely from Strasbourg, France, to Indore, India, over a distance of more than 4,000 miles [2]. - A total of 35 telesurgeries, including 10 cardiac procedures, have been successfully completed using the SSi Mantra surgical robotic system, showcasing its effectiveness in complex surgeries [5]. - The SSi Mantra system has been clinically validated in over 100 different types of surgical procedures in India, with more than 5,000 multi-specialty surgeries performed without device-related adverse events [5][9]. Technological Innovation - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, a 3D 4K monitor, and advanced imaging capabilities, enhancing the safety and efficiency of surgical procedures [9]. - The system's telesurgery capabilities address traditional barriers related to travel, time, cost, and surgical accessibility, aiming to create a more equitable medical standard [4]. Regulatory Approval - SS Innovations is the only surgical robotic company to receive regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for both teleproctoring and telesurgery, highlighting its compliance with safety and efficacy standards [6].

Core Insights - SS Innovations International, Inc. has installed over 100 SSi Mantra surgical robotic systems across India and six other countries, with more than 5,000 surgical procedures performed to date, including 240 cardiac surgeries and 32 telesurgeries [1][2] - The company aims to democratize access to robotic surgery and plans to submit a De Novo application to the U.S. FDA for marketing approval of the SSi Mantra by the end of July 2025, while also pursuing CE marking certification in the European Union by late 2025 [2] Company Overview - SS Innovations develops innovative surgical robotic technologies with a focus on affordability and accessibility for a larger segment of the global population, featuring the SSi Mantra surgical robotic system and the SSi Mudra surgical instruments [3] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Product Details - The SSi Mantra surgical robotic system is a modular, multi-arm system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models [4] - It has been clinically validated in over 100 different types of surgical procedures, supporting various specialties, including cardiac surgery [4]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant milestone in the field of robotic surgery [2][3][5] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [2][7] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [7] Surgical Procedure Details - The telesurgery involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, which are advanced bariatric procedures aimed at long-term weight loss and improved metabolic health [4][8] - The surgeries were performed remotely over a distance of 560 miles, showcasing the capabilities of the SSi Mantra 3 system with zero perceptible lag and flawless precision [3][8] Technological Advancements - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities, supporting various surgical specialties [11] - The system has been clinically validated in over 100 different types of surgical procedures in India, demonstrating its versatility and effectiveness [11] Vision and Impact - The company emphasizes its mission to democratize robotic surgery, bridging healthcare gaps and making advanced surgical care accessible to remote regions [5][6] - SS Innovations aims to redefine surgical care access, equity, and excellence through its innovative technologies and humanitarian vision [6]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant advancement in robotic surgery technology [1][4] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [5] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [5] Technological Achievement - The robotic telesurgery bridged a distance of 560 miles between Gurugram and Indore, India, performed with zero perceptible lag and flawless precision [2][7] - The procedures involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, showcasing the capabilities of the SSi Mantra 3 system [3][7] Leadership Commentary - Dr. Sudhir Srivastava, CEO, emphasized that this achievement bridges healthcare gaps and makes advanced surgical expertise accessible to remote regions [4] - Dr. Mohit Bhandari, who led the surgery, highlighted the potential of robotic telesurgery to redefine surgical care and improve access to healthcare [4] Future Vision - SS Innovations aims to continue refining its technology to enhance surgical efficiency and improve patient outcomes, particularly in underserved areas [4]

[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) This section summarizes SS Innovations' strong financial performance in Q1 2025 and outlines key business and strategic advancements [First Quarter 2025 Overview](index=1&type=section&id=First%20Quarter%202025%20Overview) SS Innovations reported record quarterly revenue of $5.1 million for Q1 2025, a 40.8% increase year-over-year, driven by higher sales of its SSi Mantra 3 surgical robotic system Q1 2025 Financial Highlights (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $5.1 million | $3.6 million | +40.8% | | Gross Profit | $1.1 million | $0.7 million | +49.3% | | Gross Margin | 21.23% | 20.02% | +121 bps | | Net Loss | $(5.7) million | $(9.8) million | Narrowed | | Net Loss per Share | $(0.03) | $(0.06) | Narrowed | | SSi Mantra Installations | 15 units | 9 units | +66.7% | Q1 2025 Revenue Breakdown and Operational Metrics (vs. Q1 2024) | Category | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | System sales | $4,502,482 | $3,494,759 | +28.8% | | Instrument sales | $477,208 | $118,515 | +302.7% | | Warranty sales | $122,504 | $9,407 | +1,202.3% | | **Total revenue** | **$5,120,610** | **$3,637,693** | **+40.8%** | | SSi Mantra installations | 15 | 9 | +67% | | Cumulative installed base | 78 | 24 | +225% | | SSi Mantra surgeries | 787 | 361 | +118% | | Cumulative surgeries | 3,568 | 981 | +264% | - The company ended the quarter with **$15.9 million** in cash and cash equivalents and zero long-term debt[5](index=5&type=chunk) [Business and Strategic Developments](index=1&type=section&id=Business%20and%20Strategic%20Developments) Following the quarter, the company uplisted its stock to the Nasdaq Capital Market, while focusing on global expansion and key operational milestones - The company is on track to submit a De Novo application for the SSi Mantra 3 system to the U.S. Food and Drug Administration (FDA) by the end of July 2025[1](index=1&type=chunk)[6](index=6&type=chunk) - SS Innovations is pursuing a European Union CE Mark decision, with a target of late 2025[6](index=6&type=chunk) - Subsequent to the quarter end, on April 25, 2025, the company's common stock was uplisted to The Nasdaq Capital Market®[3](index=3&type=chunk) - Key Q1 achievements include: - The SSi Mantra 3 system enabled the world's first robotic cardiac telesurgery - The company debuted a state-of-the-art mobile telesurgery unit in India - Received medical device regulatory approvals in the Philippines and Ukraine[9](index=9&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents the condensed consolidated balance sheets, statements of operations, and cash flows for SS Innovations, highlighting key financial positions and performance metrics [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets grew to $63.5 million from $42.4 million at year-end 2024, largely due to a significant increase in cash and inventory Balance Sheet Summary | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $15,873,217 | $466,500 | | Total Current Assets | $47,619,943 | $27,416,291 | | **Total Assets** | **$63,456,961** | **$42,385,213** | | Total Current Liabilities | $14,996,713 | $21,330,222 | | **Total Liabilities** | **$22,902,671** | **$28,928,110** | | **Total Stockholders' Equity** | **$40,554,290** | **$13,457,103** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2025, revenues increased 40.8% to $5.1 million, with a significant reduction in stock compensation expense leading to a narrowed net loss of $5.7 million Statement of Operations Summary (Three Months Ended) | Account | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Total Revenue | $5,120,610 | $3,637,693 | | Gross Profit | $1,087,208 | $728,182 | | Total Operating Expenses | $7,009,061 | $10,560,501 | | Loss from Operations | $(5,921,853) | $(9,832,319) | | **Net Loss** | **$(5,681,353)** | **$(9,841,753)** | | Net Loss Per Share (basic and diluted) | $(0.03) | $(0.06) | - Stock compensation expense decreased significantly to **$2.4 million** in Q1 2025 from **$7.1 million** in Q1 2024, which was a primary driver for the reduction in net loss[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, the company used $6.1 million in cash from operating activities, offset by $22.4 million provided by financing activities, resulting in a net increase in cash of $15.4 million Cash Flow Summary (Three Months Ended) | Activity | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,103,374) | $(2,671,918) | | Net cash used in investing activities | $(872,804) | $(127,255) | | Net cash provided by financing activities | $22,406,019 | $2,638,259 | | **Net change in cash** | **$15,429,841** | **$(160,914)** | | Cash and cash equivalents at end of period | $22,078,788 | $6,895,580 | - Financing activities were primarily driven by **$28 million** in proceeds from the issuance of convertible notes to a principal shareholder[17](index=17&type=chunk) - As a supplemental disclosure, **$30.6 million** of convertible notes, including interest, were converted into common stock during the period[17](index=17&type=chunk) [Company and Product Overview](index=2&type=section&id=Company%20and%20Product%20Overview) This section provides an overview of SS Innovations International, Inc., its mission to democratize robotic surgery, and details its flagship SSi Mantra surgical robotic system [About SS Innovations](index=2&type=section&id=About%20SS%20Innovations) SS Innovations International, Inc. is an American company, headquartered in India, that develops surgical robotic technologies with a mission to make robotic surgery affordable and accessible globally - The company's vision is to democratize robotic surgery by making it affordable and accessible to a larger segment of the global population[8](index=8&type=chunk) - The product portfolio includes the SSi Mantra surgical robotic system and SSi Mudra surgical instruments, which support various procedures including robotic cardiac surgery[8](index=8&type=chunk) [About the SSi Mantra](index=3&type=section&id=About%20the%20SSi%20Mantra) The SSi Mantra is a modular, multi-arm surgical robotic system designed for user-friendliness, featuring advanced technologies and clinical validation across over 100 surgical procedures in India - The system is modular with 3 to 5 robotic arms and features an open-faced ergonomic surgeon command center with a large 3D 4K monitor[10](index=10&type=chunk) - It utilizes over 40 different types of robotic endo-surgical instruments to support specialties including cardiac surgery[10](index=10&type=chunk) - The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures[10](index=10&type=chunk)

[PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) This section presents the company's financial statements, management's analysis, market risk disclosures, and controls and procedures [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) For Q1 2025, total assets increased to $63.5 million, liabilities decreased to $22.9 million, and net loss improved to $5.7 million, though going concern doubts persist Condensed Consolidated Balance Sheet Data (Unaudited) | Balance Sheet Items | March 31, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $15,873,217 | $466,500 | | Total Current Assets | $47,619,943 | $27,416,291 | | Total Assets | $63,456,961 | $42,385,213 | | **Liabilities & Equity** | | | | Total Current Liabilities | $14,996,713 | $21,330,222 | | Total Liabilities | $22,902,671 | $28,928,110 | | Total stockholders' equity | $40,554,290 | $13,457,103 | Condensed Consolidated Statements of Operations (Unaudited) | Income Statement Items | Three months ended March 31, 2025 ($) | Three months ended March 31, 2024 ($) | | :--- | :--- | :--- | | Total revenue | $5,120,610 | $3,637,693 | | Gross Profit | $1,087,208 | $728,182 | | Loss from operations | ($5,921,853) | ($9,832,319) | | Net Loss | ($5,681,353) | ($9,841,753) | | Net loss per share - basic and diluted | ($0.03) | ($0.06) | Condensed Consolidated Statements of Cash Flows (Unaudited) | Cash Flow Items | Three months ended March 31, 2025 ($) | Three months ended March 31, 2024 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | ($6,103,374) | ($2,671,918) | | Net cash used in investing activities | ($872,804) | ($127,255) | | Net cash provided by financing activities | $22,406,019 | $2,638,259 | | Net change in cash | $15,429,841 | ($160,914) | - The company's reliance on related parties for funding and a history of net losses raise substantial doubt about its ability to continue as a going concern, necessitating further funding for operations[26](index=26&type=chunk)[36](index=36&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=34&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management reports a 40.8% revenue increase and reduced net loss in Q1 2025, driven by higher sales and lower stock compensation, despite ongoing going concern doubts [Results of Operations](index=34&type=section&id=Results%20of%20Operations) For Q1 2025, total revenue increased to $5.1 million, gross profit rose to $1.1 million, and net loss decreased to $5.7 million due to reduced stock compensation expenses Comparison of Operations for the three months ended March 31 | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Total Revenue | $5,120,610 | $3,637,693 | | Gross profit | $1,087,208 | $728,182 | | Research & development expense | $1,010,095 | $527,991 | | Stock compensation expense | $2,379,212 | $7,108,750 | | Selling, general and administrative expense | $3,410,872 | $2,843,659 | | Loss from operations | ($5,921,853) | ($9,832,319) | | Net loss | ($5,681,353) | ($9,841,753) | - Revenue increased primarily due to the sale of an increased number of surgical robotic systems and instruments in Q1 2025 compared to Q1 2024[181](index=181&type=chunk) - The significant decrease in net loss was primarily the result of a **$4.7 million reduction** in stock compensation expense, partially offset by a **$0.57 million increase** in SG&A expenses[189](index=189&type=chunk) - Research and development expenses nearly doubled to **$1.01 million**, reflecting the company's continued focus on improving its SSi Mantra surgical robotic system[183](index=183&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) The company's Q1 2025 liquidity significantly improved due to $22.4 million in financing activities, primarily from a $28 million convertible note issuance, despite ongoing going concern doubts - In January 2025, the company raised **$28 million** from an affiliate through a 7% convertible promissory note, with **$30 million** in principal plus accrued interest subsequently converted into common stock in February and March 2025[196](index=196&type=chunk)[198](index=198&type=chunk)[199](index=199&type=chunk) Cash Flow Summary for the three months ended March 31, 2025 | Cash Flow Activity | Amount ($) | | :--- | :--- | | Net cash used in operating activities | ($6,103,374) | | Net cash used in investing activities | ($872,804) | | Net cash provided by financing activities | $22,406,019 | | **Cash at the end of period** | **$22,078,788** | - Despite recent fundraising, management states there are no committed sources of funding, raising substantial doubt about the Company's ability to continue as a going concern[207](index=207&type=chunk) [Critical Accounting Policies](index=37&type=section&id=Critical%20Accounting%20Policies) Critical accounting policies involve significant management judgment, particularly in valuing stock options and determining standalone selling prices for bundled revenue contracts - Critical accounting policies involve significant estimates, including the fair value of stock options and the standalone selling price in bundled revenue contracts[209](index=209&type=chunk) - The fair value of stock-based awards is determined at the grant date using models like Black-Scholes, which requires significant judgment on inputs like expected volatility and term[210](index=210&type=chunk)[211](index=211&type=chunk) - For sales with multiple products and services, revenue is allocated based on relative standalone selling prices, estimated using market conditions and historical data if not directly observable[214](index=214&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) This section is not applicable for the reporting period - Not applicable[217](index=217&type=chunk) [Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) As of March 31, 2025, the company's disclosure controls were ineffective due to material weaknesses, prompting a remediation plan including enhanced reviews and a new ERP system - Management concluded that the company's disclosure controls and procedures were **not effective** as of March 31, 2025[220](index=220&type=chunk) - Material weaknesses identified include: failure to properly apply U.S. GAAP, lack of written documentation of internal control policies, and insufficient segregation of duties within accounting functions[220](index=220&type=chunk) - The remediation plan includes enhancing transaction review processes, engaging external experts for guidance, and implementing a new comprehensive cloud-based ERP system[221](index=221&type=chunk)[222](index=222&type=chunk) [PART II - OTHER INFORMATION](index=41&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, unregistered equity sales, defaults, mine safety, other information, and exhibits [Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in litigation in the Bahamas regarding a disputed 9% ownership claim in its subsidiary, Otto Pvt Ltd, with the CEO providing full indemnification - In April 2024, an ex-shareholder of the subsidiary Otto Pvt Ltd initiated litigation in the Bahamas, claiming ownership of **9,000 shares** (approx. **9% interest**)[226](index=226&type=chunk) - The company asserts the shareholding was cancelled in July 2022 due to the plaintiff's failure to pay the agreed-upon consideration, and the company believes the outcome will be favorable[226](index=226&type=chunk) - The company's CEO, Dr. Sudhir Srivastava, has entered into an Indemnification Agreement to fully cover any claims, damages, and legal fees the company may incur from this litigation[227](index=227&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors.) This section is not applicable for the reporting period - Not Applicable[229](index=229&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) Between December 2024 and March 2025, the company received **$30 million** in financing from its CEO's holding company via convertible notes, which were subsequently converted into **21,858,368 shares** of common stock at **$1.38 per share** - The company received **$30 million** in financing from its CEO's holding company, Sushruta Pvt Ltd, through several tranches of one-year 7% convertible promissory notes issued between December 2024 and March 2025[230](index=230&type=chunk) - As of March 31, 2025, the entire **$30 million principal** plus **$164,548 in interest** was converted into **21,858,368 shares** of common stock at a conversion price of **$1.38 per share**[230](index=230&type=chunk) - The securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933[231](index=231&type=chunk) [Defaults Upon Senior Securities](index=41&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities.) None reported - None[232](index=232&type=chunk) [Mine Safety Disclosures](index=41&type=section&id=Item%204.%20Mine%20Safety%20Disclosures.) This section is not applicable - Not applicable[233](index=233&type=chunk) [Other Information](index=41&type=section&id=Item%205.%20Other%20Information.) None reported - None[233](index=233&type=chunk) [Exhibits](index=42&type=section&id=Item%206.%20Exhibits) The report includes Section 302 and Section 906 certifications from the CEO and CFO, along with Inline XBRL financial data files - Filed exhibits include Section 302 and 906 certifications from the CEO and CFO[234](index=234&type=chunk) - Inline XBRL documents (Instance, Schema, Calculation, Definition, Label, and Presentation) are also included as exhibits[234](index=234&type=chunk)